INCY
INCYTE CORP
Nasdaq: INCY · Wilmington, DE · Healthcare
$117.67+0.98 (+0.84%)Closed
Market Cap$23.53B
Cash$3.75Bmost recent
Runwayprofitable
P/E (TTM)18.4EPS $6.41
52-Wk Range$70.16 – $118.52
Avg Volume1.9M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$117.67+71.6%
Pipeline
Drug candidates sponsored by INCYTE · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | ruxolitinib tablets | Polycythemia Vera | Completed | 2014-01-15past | 1 | |
| Phase 3 | Pembrolizumab | Renal Cell Carcinoma (RCC)+10 more | Completed | 2019-11-07past | 4 | |
| Phase 3 | parsaclisib | Myelofibrosis+6 more | Completed | 2024-04-30past | 8 | |
| Phase 3 | Pemigatinib | Unresectable Cholangiocarcinoma+11 more | Completed | 2025-07-07past | 7 | |
| Phase 3 | Ruxolitinib | MPN (Myeloproliferative Neoplasms)+8 more | Active, not recruiting | 2026-07-13past | 11 | |
| Phase 3 | Tafasitamab | Diffuse Large B-cell Lymphoma | Active, not recruiting | 2026-09-01 | 1 | |
| Phase 3 | Povorcitinib | Hidradenitis Suppurativa (HS)+2 more | Active, not recruiting | 2026-10-19 | 4 | |
| Phase 3 | Ruxolitinib cream | Atopic Dermatitis+4 more | Recruiting | 2026-12-09 | 8 | |
| Phase 3 | INCA034176 | Chronic Graft-versus-host-disease | Recruiting | 2027-09-28 | 2 | |
| Phase 2 | Placebo | Diabetes Mellitus, Type 2+1 more | Completed | 2007-11past | 1 | |
| Phase 2 | INCB019602 | Type 2 Diabetes | Terminated | 2009-02past | 1 | |
| Phase 2 | INCB028050 | Rheumatoid Arthritis | Completed | 2010-06past | 1 | |
| Phase 1 | INCB007839 300mg BID | Breast Cancer | Terminated | 2011-09past | 1 | |
| Phase 1 | INCB047986 | MDS (Myelodysplastic Syndrome)+8 more | Terminated | 2014-09past | 2 | |
| Phase 1 | Epacadostat | Melanoma | Terminated | 2016-12-27past | 1 | |
| Phase 2 | Ruxolitinib 0.15% Cream QD | Atopic Dermatitis | Completed | 2018-01-10past | 1 | |
| Phase 1 | MK-3475 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC)+13 more | Completed | 2018-11-26past | 1 | |
| Phase 1 | Azacitidine | Solid Tumors+2 more | Terminated | 2019-02-15past | 1 | |
| Phase 2 | INCB054707 | Hidradenitis Suppurativa | Completed | 2019-08-13past | 1 | |
| Phase 1 | MEDI4736 | Solid Tumors+3 more | Completed | 2019-08-28past | 1 | |
| Phase 2 | Retifanlimab | Squamous Cell Carcinoma of Anal Canal+8 more | Completed | 2022-11-21past | 3 | |
| Phase 2 | Itacitinib | NSCLC (Non-small Cell Lung Carcinoma)+6 more | Completed | 2023-08-24past | 5 | |
| Phase 2 | INCAGN01876 | Metastatic Head and Neck Squamous Cell Carcinoma+2 more | Withdrawn | 2024-04-20past | 1 | |
| Phase 1 | INCAGN02385 | Melanoma+17 more | Completed | 2025-08-25past | 2 | |
| Phase 1 | INCB177054 | Solid Tumors+2 more | Active, not recruiting | 2026-07-30 | 1 | |
| Phase 1 | INCB099280 | Advanced Solid Tumors+2 more | Active, not recruiting | 2026-09-28 | 3 | |
| Phase 2 | INCB123667 | Ovarian Cancer+1 more | Recruiting | 2027-04-27 | 2 | |
| Phase 1 | INCB057643 | Solid Tumors+7 more | Active, not recruiting | 2027-04-30 | 2 | |
| Phase 1 | Ponatinib | Acute Myeloid Leukemia+8 more | Recruiting | 2028-02-01 | 1 | |
| Phase 1 | INCB13739 | Insulin Resistance+1 more | Completed | 2007-03past | 1 | |
| Phase 1 | INCB007839 | Solid Tumors and Hematologic Malignancy | Completed | 2009-01past | 1 | |
| Phase 1 | INCB028060 | Solid Tumor+2 more | Completed | 2012-07past | 1 | |
| Phase 1 | INCB024360 | Solid Tumors and Hematologic Malignancy | Completed | 2013-05past | 1 | |
| Phase 1 | INCB001158 | Metastatic Cancer+9 more | Completed | 2020-04-30past | 1 | |
| Phase 1 | INCB062079 | Hepatocellular Carcinoma (HCC)+5 more | Terminated | 2020-06-10past | 1 | |
| Phase 1 | INCB059872 | Sickle Cell Disease+1 more | Terminated | 2020-06-25past | 2 | |
| Phase 1 | INCB086550 | Healthy Volunteers | Completed | 2022-03-25past | 1 | |
| Phase 1 | INCB000928 | Renal Impairment+1 more | Completed | 2023-02-19past | 1 | |
| Phase 1 | Ruxolitinib IR | Healthy Participants | Completed | 2024-10-25past | 1 | |
| Phase 1 | Axatilimab | Healthy Participants | Completed | 2025-06-06past | 1 | |
| Phase 1 | Ruxolitinib Cream 1.5% | Prurigo Nodularis | Completed | 2025-07-17past | 1 | |
| Phase 1 | INCB081776 | Advanced Solid Tumors | Terminated | 2025-09-10past | 1 | |
| Phase 1 | INCB160058 | Healthy Participants+1 more | Recruiting | 2028-10-09 | 2 | |
| Phase 1 | INCA033989 | Myeloproliferative Neoplasms | Recruiting | 2028-10-29 | 1 | |
| Phase 1 | INCA33890 | Solid Tumors+2 more | Recruiting | 2029-05-03 | 1 | |
| N/A | Unnamed | MPN (Myeloproliferative Neoplasms) | Completed | 2019-08-03past | 1 | |
| N/A | Unnamed | BCR-ABL Positive Acute Lymphoblastic Leukemia | Withdrawn | 2021-03past | 1 | |
| N/A | Unnamed | Chronic Myeloid Leukemia+3 more | Completed | 2022-03-31past | 1 | |
| N/A | Unnamed | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting | 2025-06-30past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for INCY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.